

## **BAB VII**

### **DAFTAR PUSTAKA**

1. Fact Sheets by Cancer [Internet]. [cited 2017 Sep 22]. Available from:  
[http://globocan.iarc.fr/Pages/fact\\_sheets\\_cancer.aspx](http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx)
2. Vasconcelos I, Hussainzada A, Berger S, Fietze E, Linke J, Siedentopf F, et al. The St. Gallen surrogate classification for breast cancer subtypes successfully predicts tumor presenting features, nodal involvement, recurrence patterns and disease free survival. *Breast.* 2016;29(August):181–5.
3. Coates AS, Winer EP, Goldhirsch A, Gelber RD, Gnant M, Piccart-Gebhart M, et al. Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015. *Ann Oncol* [Internet]. 2015 Aug 1 [cited 2017 Nov 1];26(8):1533–46. Available from:  
<https://academic.oup.com/annonc/article-lookup/doi/10.1093/annonc/mdv221>
4. Slamon DJ. Studies of the HER-Z / neu Proto-oncogene in Human Breast Cancer. 1990;
5. Buzdar AU, Ibrahim NK, Francis D, Booser DJ, Thomas ES, Theriault RL, et al. Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: Results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. *J Clin Oncol.* 2005;23(16):3676–85.

6. Dent R, Hanna WM, Trudeau M, Rawlinson E, Sun P, Narod SA. Pattern of metastatic spread in triple-negative breast cancer. *Breast Cancer Res Treat*. 2009;115(2):423–8.
7. Choi J, Jung W-H, Koo JS. Clinicopathologic features of molecular subtypes of triple negative breast cancer based on immunohistochemical markers. *Histol Histopathol* [Internet]. 2012;27(11):1481–93. Available from: <http://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=23018247&retmode=ref&cmd=prlinks%5Cnpapers2://publication/uuid/EF27626A-3E18-4FD8-AB41-90A0016DB409>
8. Choi Y, Oh E, Park S, Kim Y, Park Y, Song K, et al. *Breast Cancers : Better Prediction Model for Survival*. 2010;
9. International Agency for Research on Cancer WHO. WHO Classification of Tumors of the Breast 4th Edition [Internet]. Vol. 1, International Agency for Research on Cancer (IARC). 2012. 240 p. Available from: [www.who.int/bookorders/%5Cnwww.styluspub.com%5Cnwww.renoufbooks.com](http://www.who.int/bookorders/%5Cnwww.styluspub.com%5Cnwww.renoufbooks.com)
10. Definition of breast cancer - NCI Dictionary of Cancer Terms - National Cancer Institute [Internet]. [cited 2017 Oct 8]. Available from: <https://www.cancer.gov/publications/dictionaries/cancer-terms?cdrid=444971>
11. Dai X, Li T, Bai Z, Yang Y, Liu X, Zhan J, et al. Breast cancer intrinsic subtype classification, clinical use and future trends. *Am J Cancer Res* [Internet]. 2015 [cited 2017 Oct 14];5(10):2929–43. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/26693050>

12. Breast Statistics | American Cancer Society - Cancer Facts & Statistics [Internet]. [cited 2017 Oct 14]. Available from: <https://cancerstatisticscenter.cancer.org/#!/cancer-site/Breast>
13. Cancer Statistics Review, 1975-2014 - SEER Statistics [Internet]. [cited 2017 Nov 5]. Available from: [https://seer.cancer.gov/csr/1975\\_2014/](https://seer.cancer.gov/csr/1975_2014/)
14. Breast Cancer Facts & Figures 2017-2018. 2017.
15. Gierach GL, Curtis RE, Pfeiffer RM, Mullooly M, Ntowe EA, Hoover RN, et al. Association of Adjuvant Tamoxifen and Aromatase Inhibitor Therapy With Contralateral Breast Cancer Risk Among US Women With Breast Cancer in a General Community Setting. *JAMA Oncol* [Internet]. 2017;3(2):186. Available from: <http://oncology.jamanetwork.com/article.aspx?doi=10.1001/jamaoncol.2016.3340>
16. Shah R, Rosso K, Nathanson SD. Pathogenesis, prevention, diagnosis and treatment of breast cancer. *World J Clin Oncol* [Internet]. 2014 Aug 10 [cited 2017 Oct 14];5(3):283–98. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/25114845>
17. Collaborative Group on Hormonal Factors in Breast Cancer. Familial breast cancer: collaborative reanalysis of individual data from 52 epidemiological studies including 58,209 women with breast cancer and 101,986 women without the disease. *Lancet* (London, England) [Internet]. 2001;358(9291):1389–99. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/11705483>
18. Margolin S, Johansson H, Rutqvist LE, Lindblom A, Fornander T. Family history, and impact on clinical presentation and prognosis, in a population-based breast cancer cohort from the Stockholm County. *Fam Cancer*. 2006;5(4):309–21.

19. Sharif S, Moran A, Huson SM, Iddenden R, Shenton A, Howard E, et al. Women with neurofibromatosis 1 are at a moderately increased risk of developing breast cancer and should be considered for early screening. *J Med Genet* [Internet]. 2007;44(8):481–4. Available from: <http://jmg.bmjjournals.org/cgi/doi/10.1136/jmg.2007.049346>
20. King M-C. Breast and Ovarian Cancer Risks Due to Inherited Mutations in BRCA1 and BRCA2. *Science* (80- ) [Internet]. 2003;302(5645):643–6. Available from: <http://www.sciencemag.org/cgi/doi/10.1126/science.1088759>
21. Ford D, Easton DF, Stratton M, Narod S, Goldgar D, Devilee P, et al. Genetic Heterogeneity and Penetrance Analysis of the BRCA1 and BRCA2 Genes in Breast Cancer Families. *Am J Hum Genet* [Internet]. 1998;62(3):676–89. Available from: <http://linkinghub.elsevier.com/retrieve/pii/S0002929707638488>
22. Antoniou A, Pharoah PDP, Narod S, Risch HA, Eyfjord JE, Hopper JL, et al. Average Risks of Breast and Ovarian Cancer Associated with BRCA1 or BRCA2 Mutations Detected in Case Series Unselected for Family History: A Combined Analysis of 22 Studies. *Am J Hum Genet* [Internet]. 2003;72(5):1117–30. Available from: <http://linkinghub.elsevier.com/retrieve/pii/S0002929707606405>
23. Seal S, Thompson D, Renwick A, Elliott A, Kelly P, Barfoot R, et al. Truncating mutations in the Fanconi anemia J gene BRIP1 are low-penetrance breast cancer susceptibility alleles. *Nat Genet* [Internet]. 2006;38(11):1239–41. Available from: <http://www.nature.com/doifinder/10.1038/ng1902>
24. Wong MW, Nordfors C, Mossman D, Pecenpetelovska G, Avery-Kiejda KA, Talseth-Palmer B, et al. BRIP1, PALB2, and RAD51C mutation analysis reveals their relative importance as genetic susceptibility factors for breast cancer. *Breast Cancer Res Treat*. 2011;127(3):853–9.

25. van den Brandt PA, Spiegelman D, Yaun S-SS, Adami H-O, Beeson L, Folsom AR, et al. Pooled analysis of prospective cohort studies on height, weight, and breast cancer risk. *Am J Epidemiol.* 2000;152(6):514–27.
26. Green J, Cairns BJ, Casabonne D, Wright FL, Reeves G, Beral V. Height and cancer incidence in the Million Women Study: prospective cohort, and meta-analysis of prospective studies of height and total cancer risk. *Lancet Oncol* [Internet]. 2011;12(8):785–94. Available from: [http://dx.doi.org/10.1016/S1470-2045\(11\)70154-1](http://dx.doi.org/10.1016/S1470-2045(11)70154-1)
27. Wirén S, Häggström C, Ulmer H, Manjer J, Bjørge T, Nagel G, et al. Pooled cohort study on height and risk of cancer and cancer death. *Cancer Causes Control* [Internet]. 2014;25(2):151–9. Available from: <http://link.springer.com/10.1007/s10552-013-0317-7>
28. Rosner B, Colditz GA, Willett WC. Reproductive Risk Factors in a Prospective Study of Breast Cancer: The Nurses' Health Study. *Am J Epidemiol* [Internet]. 1994;139(8):819–35. Available from: <https://academic.oup.com/aje/article/131909/Reproductive>
29. Lambertini M, Santoro L, Del Mastro L, Nguyen B, Livraghi L, Ugolini D, et al. Reproductive behaviors and risk of developing breast cancer according to tumor subtype: A systematic review and meta-analysis of epidemiological studies. *Cancer Treat Rev* [Internet]. 2016;49:65–76. Available from: <http://dx.doi.org/10.1016/j.ctrv.2016.07.006>
30. Albrektsen G, Heuch I, Hansen S, Kvåle G. Breast cancer risk by age at birth, time since birth and time intervals between births: exploring interaction effects. *Br J Cancer* [Internet]. 2005;92(1):167–75. Available from: <http://www.nature.com/doifinder/10.1038/sj.bjc.6602302>

31. Schedin P. Pregnancy-associated breast cancer and metastasis. *Nat Rev Cancer* [Internet]. 2006;6(4):281–91. Available from: <http://www.nature.com/doifinder/10.1038/nrc1839>
32. Beral V, Bull D, Doll R, Peto R, Reeves G. Breast cancer and breastfeeding: Collaborative reanalysis of individual data from 47 epidemiological studies in 30 countries, including 50 302 women with breast cancer and 96 973 women without the disease. *Lancet*. 2002;360(9328):187–95.
33. Sieri S, Krogh V, Bolelli G, Abagnato CA, Grioni S, Pala V, et al. Sex Hormone Levels, Breast Cancer Risk, and Cancer Receptor Status in Postmenopausal Women: the ORDET Cohort. *Cancer Epidemiol Biomarkers Prev* [Internet]. 2009;18(1055–9965 (Print)):169–76. Available from: file:///c/Users/kroghvittorio/Documents/Dati/Personal/CV/PDF/vk241.pdf
34. Kelsey JL, Gammon MD, John EM. Reproductive factors and breast cancer. *Epidemiol Rev*. 1993;15(1):36–47.
35. Rosenheck RA, Perkins DO, Keefe RSE, Ph D, Davis SM, Davis CE, et al. Benign Breast Disease and the Risk of Breast Cancer. *New Engl J*. 2005;1209–23.
36. Dupont WD, Parl FF, Hartmann WH, Brinton LA, Winfield AC, Worrell JA, et al. Breast cancer risk associated with proliferative breast disease and atypical hyperplasia. *Cancer*. 1993;71(4):1258–65.
37. Bertrand KA, Scott CG, Tamimi RM, Jensen MR, Pankratz VS, Norman AD, et al. Dense and nondense Mammographic area and risk of breast cancer by age and tumor characteristics. *Cancer Epidemiol Biomarkers Prev*. 2015;24(5):798–809.

38. Sprague BL, Gangnon RE, Burt V, Trentham-Dietz A, Hampton JM, Wellman RD, et al. Prevalence of mammographically dense breasts in the United States. *J Natl Cancer Inst.* 2014;106(10).
39. Harris HR, Tamimi RM, Willett WC, Hankinson SE, Michels KB. Body size across the life course, mammographic density, and risk of breast cancer. *Am J Epidemiol.* 2011;174(8):909–18.
40. Boyd NF. Tamoxifen, mammographic density, and breast cancer prevention. *J Natl Cancer Inst.* 2011;103(9):704–5.
41. Byrne C, Ursin G, Martin CF, Peck JD, Cole EB, Zeng D, et al. Mammographic Density Change With Estrogen and Progestin Therapy and Breast Cancer Risk. *J Natl Cancer Inst.* 2017;109(9):1–7.
42. Lahmann PH, Hoffmann K, Allen N, Van Gils CH, Khaw KT, Tehard B, et al. Body size and breast cancer risk: Findings from the European Prospective Investigation into Cancer and Nutrition (EPIC). *Int J Cancer.* 2004;111(5):762–71.
43. Cancer CG on HF in B. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52 705 women with breast cancer and 108 411 women without breast cancer. *Lancet* [Internet]. 1997;350(9084):1047–59. Available from: <http://linkinghub.elsevier.com/retrieve/pii/S0140673697082330>
44. Macacu A, Autier P, Boniol M, Boyle P. Active and passive smoking and risk of breast cancer: a meta-analysis. *Breast Cancer Res Treat.* 2015;154(2):213–24.
45. Dossus L, Boutron-Ruault MC, Kaaks R, Gram IT, Vilier A, Fervers B, et al. Active and passive cigarette smoking and breast cancer risk: Results from the EPIC cohort. *Int J Cancer.* 2014;134(8):1871–88.

46. Gaudet MM, Gapstur SM, Sun J, Ryan Diver W, Hannan LM, Thun MJ. Active smoking and breast cancer risk: Original cohort data and meta-analysis. *J Natl Cancer Inst.* 2013;105(8):515–25.
47. White AJ, D'Aloisio AA, Nichols HB, DeRoo LA, Sandler DP. Breast cancer and exposure to tobacco smoke during potential windows of susceptibility. *Cancer Causes Control.* 2017;28(7):667–75.
48. Lahmann PH, Hoffmann K, Allen N, van Gils CH, Khaw K-T, Tehard B, et al. Body size and breast cancer risk: Findings from the European prospective investigation into cancer and nutrition (EPIC). *Int J Cancer* [Internet]. 2004 Sep 20 [cited 2017 Oct 18];111(5):762–71. Available from: <http://doi.wiley.com/10.1002/ijc.20315>
49. Milazzo G, Giorgino F, Damante G, Sung C, Stampfer MR, Vigneri R, et al. Insulin receptor expression and function in human breast cancer cell lines. *Cancer Res* [Internet]. 1992;52(14):3924–30. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/1617668>
50. American Cancer Society. Breast Cancer Staging 7th Edition. *Am Jt Comm Cancer* [Internet]. 2010;1–2. Available from: [cancerstaging.org](http://cancerstaging.org)
51. Jung HA, Park YH, Kim M, Kim S, Chang WJ. Prognostic relevance of biological subtype overrides that of TNM staging in breast cancer : discordance between stage and biology. 2015;1073–9.
52. Hennigs A, Riedel F, Gondos A, Sinn P, Schirmacher P, Marmé F, et al. Prognosis of breast cancer molecular subtypes in routine clinical care: A large prospective cohort study. *BMC Cancer* [Internet]. 2016;16(1):734. Available from: <http://bmccancer.biomedcentral.com/articles/10.1186/s12885-016-2766-3>

